Edition:
United Kingdom

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

1.50USD
6:41pm GMT
Change (% chg)

$-0.17 (-10.42%)
Prev Close
$1.68
Open
$1.68
Day's High
$1.68
Day's Low
$1.50
Volume
147,287
Avg. Vol
142,363
52-wk High
$8.00
52-wk Low
$1.35

Summary

Name Age Since Current Position

Leon Moulder

59 2013 Independent Chairman of the Board

Maxine Gowen

59 President, Chief Executive Officer, Director

Roberto Cuca

47 2013 Chief Financial Officer, Senior Vice President

Michael Lark

57 2011 Senior Vice President - Research, Chief Scientific Officer

John Limongelli

46 2014 Senior Vice President, General Counsel, Corporate Secretary

Carrie Bourdow

54 2015 Senior Vice President, Chief Commercial Officer

Yacoub Habib

2015 Senior Vice President - Business Development and Corporate Planning

David Soergel

47 Senior Vice President - Clinical Development , Chief Medical Officer

Michael Dougherty

59 2013 Independent Director

Adam Koppel

47 2014 Independent Director

Julie McHugh

52 2014 Independent Director

Jake Nunn

46 2013 Independent Director

Anne Phillips

61 2014 Independent Director

Barbara Yanni

60 2014 Independent Director

Biographies

Name Description

Leon Moulder

Mr. Leon O. Moulder, Jr., is Independent Chairman of the Board of Trevena Inc. Since June 2010, Mr. Moulder has served as Chief Executive Officer and a member of the board of directors of TESARO, Inc., or TESARO, a public biopharmaceutical company. From April 2009 to January 2010, Mr. Moulder served as Vice Chairman, President and Chief Executive Officer of Abraxis BioScience, Inc., or Abraxis, a biotechnology company. Before that, Mr. Moulder served as Vice Chairman of Eisai Corporation, North America, or Eisai, a pharmaceutical company and wholly owned subsidiary of Eisai Co., Ltd., a Japanese pharmaceutical company, from January 2008 until January 2009, after Eisai acquired MGI PHARMA, Inc., a biopharmaceutical company, where he had served as President and Chief Executive Officer since May 2003. Mr. Moulder currently serves on the board of directors of Cubist Pharmaceuticals, Inc. and also serves on the Board of Trustees of Temple University as well as the Board of Visitors of the Temple University School of Pharmacy. Our board of directors believes that Mr. Moulder's significant operational and senior management experience in the pharmaceutical and biotechnology industries, as well as his extensive experience serving on boards of directors of public and private companies in the life sciences industry, allow him to make valuable contributions to the board.

Maxine Gowen

Dr. Maxine Gowen has served as our President and Chief Executive Officer and as a member of our board of directors since our founding in November 2007. Prior to joining our company, Dr. Gowen was Senior Vice President for the Center of Excellence for External Drug Discovery at GlaxoSmithKline plc, or GSK, where she held a variety of leadership positions during her tenure of 15 years. Before GSK, Dr. Gowen was Senior Lecturer and Head, Bone Cell Biology Group, Department of Bone and Joint Medicine, of the University of Bath, U.K. Dr. Gowen has served as a director of Akebia Therapeutics, Inc. since July 2014. From 2008 until 2012, Dr. Gowen served as a director of Human Genome Sciences, Inc., a public biopharmaceutical company. She received her Ph.D. from the University of Sheffield, U.K., an M.B.A. with academic honors from The Wharton School of the University of Pennsylvania, and a B.Sc. with Honors in Biochemistry from the University of Bristol, U.K.

Roberto Cuca

Mr. Roberto E. Cuca is Chief Financial Officer, Senior Vice President of Trevena, Inc. Prior to joining us, Mr. Cuca joined our company as Senior Vice President and Chief Financial Officer in September 2013. Prior to joining us, he held various leadership positions in the finance organization of Endo Health Solutions Inc., a pharmaceutical company, from March 2010 to August 2013, including, most recently, Treasurer and Senior Vice President, Finance. Prior to that, he was Director, Corporate and Business Development, at moksha8 Pharmaceuticals, Inc., an emerging markets-focused pharmaceutical company, from March 2008 until February 2010. From 2005 until 2008, he worked at JPMorgan Chase & Co. as an equity analyst covering U.S. pharmaceutical companies. Mr. Cuca received an M.B.A. from the Wharton School of The University of Pennsylvania, a J.D. from Cornell Law School and an A.B. from Princeton University, and he is a CFA charterholder.

Michael Lark

Dr. Michael W. Lark, Ph.D. is no longer Senior Vice President - Research, Chief Scientific Officer of Trevena, Inc. effective as of December 15, 2017. Prior to joining our company, Dr. Lark has served in a number of capacities with our company since February 2008, and currently serves as our Chief Scientific Officer and Senior Vice President, Research, a position he has held since March 2011. Prior to joining our company, he was Vice President of Biology at Centocor Inc., a division of Johnson & Johnson, or Centocor, from 2004 until 2008 and the Senior Director of Cardiovascular and Metabolic Diseases at Centocor from 2002 to 2004. Prior to that, Dr. Lark was Director of Musculoskeletal Diseases at GSK, from 1999 until 2002. Dr. Lark received his Ph.D. in Molecular Biology and Microbiology from the Case Western Reserve University Medical School and his B.S. in Microbiology from the Pennsylvania State University.

John Limongelli

Mr. John M. Limongelli, Esq. joined our company as Senior Vice President, General Counsel and Corporate Secretary in May 2014. Prior to that, he was Vice President, Associate Chief Counsel and Corporate Secretary at Cigna Corporation from September 2013 until May 2014. From October 2012 to September 2013, he was a partner at the law firm Royer Cooper Cohen Braunfeld LLC. He served as Senior Vice President, General Counsel and Secretary at Adolor Corporation from September 2008 until Adolor's sale to Cubist Pharmaceuticals, Inc. in December 2011. Prior to Adolor, Mr. Limongelli held roles of increasing responsibility with Cephalon, Inc., most recently serving as Vice President and Associate General Counsel. Mr. Limongelli began his legal career in private practice with Morgan, Lewis & Bockius, LLP, in Philadelphia, Pennsylvania. Prior to his legal career, Mr. Limongelli was a certified public accountant with KPMG LLP. Mr. Limongelli obtained both his J.D. and M.B.A. from Temple University.

Carrie Bourdow

Ms. Carrie L. Bourdow is Senior Vice President, Chief Commercial Officer of Trevena, Inc. Ms. Bourdow brings over 25 years of experience in pharmaceutical sales and marketing. Most recently, she was vice president of marketing, reimbursement, and operations at Cubist Pharmaceuticals, Inc., where she led launch strategy, marketing, reimbursement, and operations for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues. Prior to joining Cubist in 2013, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across several therapeutic areas including anti-infectives, acute heart failure, and pain. Ms. Bourdow has a Bachelor of Arts degree from Hendrix College and earned her Masters in Business Administration from Southern Illinois University.

Yacoub Habib

Dr. Yacoub Habib, Ph.D., M.B.A., is Senior Vice President - Business Development and Corporate Planning of Trevena, Inc. Dr. Habib joins Trevena from Ikaria, Inc. where he served as vice president of business development and led the business development strategy for the company until its acquisition. From 2007 to 2009, he served as executive director of new business development for Pfizer and participated in the creation of new business development strategies in areas outside of Pfizer's core competency markets. Before joining Pfizer, Dr. Habib was executive director of global business development for Organon Pharmaceuticals, a division of Akzo Nobel, where he was responsible for the identification, evaluation and negotiation of in-licensing, out-licensing and divestiture opportunities in neuroscience, fertility, and women's health. He started his career at Bristol-Myers Squibb where he spent nine years in various research, corporate, and business development roles including as director of corporate and business development. Dr. Habib holds a Ph.D. in pharmaceutical sciences from the University of Maryland and an M.B.A. with a major in finance and marketing from New York University Stern School of Business.

David Soergel

Dr. David Soergel has served in multiple positions since joining our company in November 2009 and currently serves as our Senior Vice President, Clinical Development and Chief Medical Officer. Prior to joining our company, he served as Senior Director, Clinical Development for Concert Pharmaceuticals, Inc., a biotechnology company, from July 2008 to November 2009. Prior to Concert, Dr. Soergel served as Director, Discovery Medicine, in the Cardiovascular Urogenital Center of Excellence in Drug Discovery at GSK, from 2005 until 2008. Dr. Soergel received an M.D. from Cornell University Medical College and a B.A. from The Johns Hopkins University. Dr. Soergel completed his clinical training in pediatric cardiology at Johns Hopkins Hospital and underwent additional training in heart failure and transplant at the Children's Hospital of Philadelphia.

Michael Dougherty

Mr. Michael R. Dougherty is Independent Director of Trevena Inc. Mr. Dougherty was Chief Executive Officer and a member of the board of directors of Kalidex Pharmaceuticals, Inc., or Kalidex, from May 2012 to October 2012. Mr. Dougherty was the President and Chief Executive Officer of Adolor Corporation, or Adolor, a biopharmaceutical company, and was a member of the board of directors of Adolor from December 2006 until December 2011. Mr. Dougherty joined Adolor as Senior Vice President of Commercial Operations in November 2002, and until his appointment as President and Chief Executive Officer in December 2006, served in a number of capacities, including Chief Operating Officer and Chief Financial Officer. From November 2000 to November 2002, Mr. Dougherty was President and Chief Operating Officer of Genomics Collaborative, Inc. Previously, Mr. Dougherty served in a variety of senior positions at Genaera Corporation, or Genaera, a biotechnology company, including President and Chief Executive Officer, and at Centocor. Mr. Dougherty is currently on the board of directors at Viropharma Incorporated, Biota Pharmaceuticals, Inc., Cempra, Inc., and Celator Pharmaceuticals, Inc. and one private company.

Adam Koppel

Dr. Adam M. Koppel, M.D., Ph.D., is Director of Trevena, Inc., effective September 17, 2014. Dr. Koppel is Senior Vice President and Chief Strategy Officer at Biogen Idec, where he has served since May 2014. Previously, he was a managing director at Brookside Capital, the public equity affiliate of Bain Capital, which he joined in 2003. Prior to Brookside Capital, he was an associate principal of the McKinsey Healthcare Practice. Dr. Koppel holds Bachelor and Master of Arts degrees in History and Science from Harvard College and earned an M.D. and Ph.D. in Molecular Neurobiology from the University of Pennsylvania. He also received an M.B.A. from the University of Pennsylvania’s Wharton School. Dr. Koppel also serves on the board of directors of PTC Therapeutics.

Julie McHugh

Ms. Julie H. McHugh is Independent Director of the Company. Ms. McHugh has over 28 years of experience in the drug development industry. From 2004 to 2006 she was president of Centocor, Inc., a J&J subsidiary, where she oversaw the development and launch of Remicade® (infliximab). From 2006 to 2008, she served as company group chairman for Johnson & Johnson’s worldwide virology business unit, where she oversaw the launches of Prezista® (darunavir) and Intelence® (etravirine). Most recently she served as chief operating officer at Endo Health Solutions Inc. from 2010 to 2013. Prior to this, she served as chief executive officer of Nora Therapeutics, Inc., a private biotech company focused on developing novel therapies for the treatment of infertility disorders. Ms. McHugh currently serves on the board of directors for Ironwood Pharmaceuticals and Xellia Pharmaceuticals, Inc., and previously served as a director for ViroPharma Incorporated. Ms. McHugh received her Masters of Business Administration degree from St. Joseph’s University and her Bachelor of Science degree from Pennsylvania State University.

Jake Nunn

Mr. Jake R. Nunn is Independent Director of Trevena Inc. Mr. Nunn has been a Partner at New Enterprise Associates, Inc., a venture capital firm, since 2006. From January 2001 to June 2006, Mr. Nunn served as a Partner and an analyst for the MPM BioEquities Fund, a public life sciences fund at MPM Capital, L.P., a private equity firm. Previously, Mr. Nunn was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex, Brown & Sons. Mr. Nunn is currently on the boards of directors at Hyperion Therapeutics, Inc., Transcept Pharmaceuticals, Inc. and three private companies. Mr. Nunn received an M.B.A. from the Stanford University Graduate School of Business and an A.B. in Economics from Dartmouth College. Mr. Nunn holds the Chartered Financial Analyst designation, and is a member of the CFA Society of San Francisco.

Anne Phillips

Dr. Anne M. Phillips, M.D. is Independent Director of Company. Dr. Phillips currently is Senior Vice President of Clinical, Medical and Regulatory Affairs at Novo Nordisk Inc., a pharmaceutical company, where she has served since 2011. Previously, she served as a Vice President in various positions at GlaxoSmithKline plc, which she joined in 1998, and prior to this Dr. Phillips was Head of the Infectious Diseases Program and Deputy Physician-in-Chief at Wellesley Central Hospital/St. Michael’s Hospital in Toronto. She is a Fellow of The Royal College of Physicians and Surgeons of Canada, earned an MD from the University of Toronto and received a BSc from the University of Western Ontario.

Barbara Yanni

Ms. Barbara Yanni is Independent Director of the Company. Ms. Yanni had a 28-year career at Merck & Co., Inc., where she was vice president and chief licensing officer before her retirement in March 2014. For 12 years, she led Merck’s Corporate Licensing group, successfully structuring and negotiating agreements to acquire rights to over one hundred compounds, programs, and technologies to enhance Merck’s pipeline. Prior to this, Ms. Yanni served in various roles including in corporate development, financial evaluation, and tax. Ms. Yanni has a J.D. from Stanford Law School and an A.B. from Wellesley College. She also holds a Masters of Law in Taxation from New York University.